CorMedix Inc (NASDAQ:CRMD - Get Free Report) CFO Susan Blum bought 5,000 shares of the firm's stock in a transaction on Thursday, November 19th. The shares were acquired at an average cost of $4.58 per share, with a total value of $22,900.00. Following the purchase, the chief financial officer directly owned 129,315 shares of the company's stock, valued at approximately $592,262.70. This represents a 4.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
CorMedix Stock Up 3.7%
Shares of CRMD stock traded up $0.19 during trading hours on Friday, hitting $5.27. 3,608,278 shares of the company's stock traded hands, compared to its average volume of 1,649,547. The stock's fifty day simple moving average is $6.91 and its two-hundred day simple moving average is $7.50. CorMedix Inc has a 12-month low of $4.47 and a 12-month high of $13.02. The stock has a market cap of $419.18 million, a price-to-earnings ratio of 7.64, a PEG ratio of 1.03 and a beta of 1.48. The company has a quick ratio of 2.36, a current ratio of 2.43 and a debt-to-equity ratio of 0.31.
CorMedix (NASDAQ:CRMD - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The company had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a return on equity of 26.70% and a net margin of 15.49%. On average, analysts expect that CorMedix Inc will post 0.44 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have commented on CRMD. Citigroup reissued a "market outperform" rating on shares of CorMedix in a report on Tuesday, November 10th. UBS Group set a $19.00 target price on CorMedix in a research note on Tuesday, November 10th. Needham & Company LLC raised their price target on CorMedix from $12.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, November 10th. Weiss Ratings lowered CorMedix from a "hold (c+)" rating to a "hold (c)" rating in a research report on Tuesday, November 10th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a research report on Friday, November 13th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $15.22.
Get Our Latest Research Report on CRMD
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of CorMedix by 13.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,222 shares of the company's stock valued at $113,000 after acquiring an additional 1,736 shares in the last quarter. HighTower Advisors LLC raised its holdings in CorMedix by 8.2% in the 2nd quarter. HighTower Advisors LLC now owns 32,655 shares of the company's stock worth $256,000 after acquiring an additional 2,476 shares during the last quarter. Sigma Planning Corp raised its holdings in CorMedix by 8.5% in the 3rd quarter. Sigma Planning Corp now owns 32,142 shares of the company's stock worth $247,000 after acquiring an additional 2,531 shares during the last quarter. Advisors Asset Management Inc. bought a new position in CorMedix in the 3rd quarter valued at approximately $26,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in CorMedix in the 3rd quarter valued at approximately $31,000. Institutional investors own 34.18% of the company's stock.
About CorMedix
(
Get Free Report)
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.